Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Microsatellite Stable

Tundra lists 3 Microsatellite Stable clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07500298

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-30

1 state

Phase 1
SAR445877
FOlfox6
+4
ACTIVE NOT RECRUITING

NCT03983993

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

This phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and panitumumab may work better in treating patients with colorectal cancer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-01-05

1 state

Advanced Microsatellite Stable Colorectal Carcinoma
Metastatic Microsatellite Stable Colorectal Carcinoma
Microsatellite Stable
+3
ACTIVE NOT RECRUITING

NCT05572684

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors

Gender: All

Ages: 18 Years - Any

Updated: 2024-12-16

11 states

Advanced or Metastatic Solid Tumors
Microsatellite Instability Low
Microsatellite Instability High
+9